Key Drivers
- Strong Liquidity
- Heavy Cash Burn
- Weak Profitability
AIAI Summary
MESO has evolved into a commercial-stage biotech with RYONCIL's strong early revenue and near-100% gross margins, but investors should require sustained quarterly uptake and shrinking cash burn before underwriting its premium valuation or pipeline upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Heavy Cash Burn
- •Weak Profitability
MESO has adequate liquidity and low debt, but persistent losses, cash burn, intangible-heavy assets, and expensive sales/book multiples make its current valuation difficult to justify.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support rebound
- •Oversold momentum
MESO remains bearish over the last month, with support at $14.41 and a rebound suggesting oversold buying interest, but a move above $15.50 is needed to improve the outlook.
Rebounded from $14.41 to $15.13 in two sessions
Sentiment & News
Key News Insights:
- •Revenue growth
- •RYONCIL uptake
- •Technical strength
Mesoblast's strong FY2026 revenue, RYONCIL commercialization momentum, and positive technical breakout signal improving growth prospects, though valuation risk remains relevant.
The updates are broadly positive for Mesoblast shares, supported by commercial execution and improving market sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings